Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment ... Regulators can expand approval for medicines if new data shows them to be effective in other therapeutic ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co ... easing knee arthritis pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to severe ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

"The approval is the second indication for Zepbound, which was approved for weight loss ... the new FDA green light doesn't expand the number of people who may be eligible for the drug, since ...